Ganciclovir

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Ganciclovir

Examples of brand names: Cymeven [DE]

ATC code: J05AB06

Main use (for orientation): CMV infection

Documented research summary

In a specially engineered GFAP–thymidine kinase mouse model, ganciclovir prevented neurogenesis and thus the anxiolytic CBD effect. This is not evidence of ordinary ganciclovir–CBD antagonism in human therapy.

Uncertainties and limitations

Transgenic ablation tool; the genetic prerequisite is indispensable for interpretation, not clinical efficacy or safety evidence. Missing data do not establish safety.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

CBD – laboratory and animal studies

Finding ID: B0450

Type of result: Genetic ablation tool; not ordinary clinical pair antagonism

Observation: The anxiolytic CBD effect disappeared following neurogenesis ablation.

Mechanism: Ganciclovir eliminated neurogenesis in the GFAP–thymidine kinase model, thereby removing a prerequisite for the investigated CBD effect

Study type: Genetically engineered transgenic mouse model

Context studied: Special GFAP–thymidine kinase transgenic mice; original abstract assessed.

Clinical interpretation: Mechanistic research context only, not a clinical decision rule.

Limitations and uncertainties: The genetic construct is crucial. No evidence that ganciclovir antagonises CBD in ordinary human therapy; do not extrapolate to valganciclovir.

Original sources for this finding: The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system. [VE_MED_23298518]

References and access status

[VE_LABEL_D0316] GANCICLOVIR (GANCICLOVIR SODIUM) INJECTION, SOLUTION [SAGENT PHARMACEUTICALS]

Original source / bibliographic reference

Authors: Respective marketing authorisation holder; regulatory product information

Year: 2026

Source type: Product information / SmPC / US Prescribing Information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[VE_MED_23298518] The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system.

Original source / bibliographic reference

Authors: Campos AC, Ortega Z, Palazuelos J, Fogaça MV, Aguiar DC, Díaz-Alonso J, Ortega-Gutiérrez S, Vázquez-Villa H, Moreira FA, Guzmán M, Galve-Roperh I, Guimarães FS.

Year: 2013

Source type: Research Support, Non-U.S. Gov't; Journal Article

DOI: 10.1017/s1461145712001502

PMID: 23298518

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility